Vascular Biogenics Ltd Company Profile (NASDAQ:VBLT)

About Vascular Biogenics Ltd (NASDAQ:VBLT)

Vascular Biogenics Ltd logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VBLT
  • CUSIP: N/A
  • Web: www.vblrx.com
Capitalization:
  • Market Cap: $149.33 million
  • Outstanding Shares: 26,907,000
Average Prices:
  • 50 Day Moving Avg: $5.70
  • 200 Day Moving Avg: $5.39
  • 52 Week Range: $3.51 - $7.58
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.30
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.42 per share
  • Price / Book: 3.91
Profitability:
  • EBIDTA: ($16,520,000.00)
  • Return on Equity: -35.53%
  • Return on Assets: -32.27%
Debt:
  • Current Ratio: 13.13%
  • Quick Ratio: 13.13%
Misc:
  • Average Volume: 100,833 shs.
  • Beta: -3.27
  • Short Ratio: 1.64
 

Frequently Asked Questions for Vascular Biogenics Ltd (NASDAQ:VBLT)

What is Vascular Biogenics Ltd's stock symbol?

Vascular Biogenics Ltd trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics Ltd's earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. View Vascular Biogenics Ltd's Earnings History.

Where is Vascular Biogenics Ltd's stock going? Where will Vascular Biogenics Ltd's stock price be in 2017?

4 brokers have issued twelve-month target prices for Vascular Biogenics Ltd's stock. Their forecasts range from $11.00 to $20.00. On average, they expect Vascular Biogenics Ltd's stock price to reach $14.75 in the next year. View Analyst Ratings for Vascular Biogenics Ltd.

What are analysts saying about Vascular Biogenics Ltd stock?

Here are some recent quotes from research analysts about Vascular Biogenics Ltd stock:

  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (5/16/2017)
  • 2. Piper Jaffray Companies analysts commented, "At the previous Nov '16 update, the study achieved its primary endpoint of 6-month PFS at therapeutic doses, as well as an intriguing overall survival benefit. However, today's update demonstrates a PFS-6 benefit of 47% vs 25% for therapeutic versus sub-therapeutic doses of VB-111, and confirmed a survival benefit, with mOS at 684 days in the therapeutic cohort. We see these results as meaningful in patients who had progressed on prior therapies including TKi's, and the safety and efficacy profile in this third tumor type reduces risk for VB-111 and the broader platform. That said, we don't expect VBL to pursue a Phase IIb/III trial in thyroid at this time, in favor of focusing on ongoing rGBM and soon-to-be-initiated ovarian cancer studies. In advance of clinical updates from those during 2017, we reiterate OW." (2/21/2017)

Who are some of Vascular Biogenics Ltd's key competitors?

Who are Vascular Biogenics Ltd's key executives?

Vascular Biogenics Ltd's management team includes the folowing people:

  • Dror Harats M.D., Chief Executive Officer, Founder, Director
  • Amos Ron, Chief Financial Officer
  • Jacob George M.D., Chief Scientific Officer
  • Eyal Breitbart Ph.D., Vice President - Research and Operations
  • Erez Feige, Vice President - Business Operations
  • Yael Cohen M.D., Vice President - Clinical Development
  • Naamit Sher Ph.D., Vice President - Drug Development and Regulatory Affairs
  • Ayelet Horn, General Counsel, Company Secretary
  • Bennett M. Shapiro M.D., Non-Executive Independent Chairman of the Board
  • Ruth Alon, Non-Executive Independent Director

Who owns Vascular Biogenics Ltd stock?

Vascular Biogenics Ltd's stock is owned by many different of retail and institutional investors. Top institutional investors include First Eagle Investment Management LLC (3.32%), Menta Capital LLC (0.45%), Turner Investments LLC (0.30%), KCG Holdings Inc. (0.17%) and Nexthera Capital LP (0.12%). View Institutional Ownership Trends for Vascular Biogenics Ltd.

Who sold Vascular Biogenics Ltd stock? Who is selling Vascular Biogenics Ltd stock?

Vascular Biogenics Ltd's stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC and First Eagle Investment Management LLC. View Insider Buying and Selling for Vascular Biogenics Ltd.

Who bought Vascular Biogenics Ltd stock? Who is buying Vascular Biogenics Ltd stock?

Vascular Biogenics Ltd's stock was purchased by a variety of institutional investors in the last quarter, including KCG Holdings Inc. and Menta Capital LLC. View Insider Buying and Selling for Vascular Biogenics Ltd.

How do I buy Vascular Biogenics Ltd stock?

Shares of Vascular Biogenics Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Biogenics Ltd's stock price today?

One share of Vascular Biogenics Ltd stock can currently be purchased for approximately $5.55.


MarketBeat Community Rating for Vascular Biogenics Ltd (NASDAQ VBLT)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vascular Biogenics Ltd (NASDAQ:VBLT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.75 (165.77% upside)

Analysts' Ratings History for Vascular Biogenics Ltd (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017HC WainwrightReiterated RatingBuy$11.00LowView Rating Details
2/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
11/29/2016Chardan CapitalSet Price TargetBuy$20.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00N/AView Rating Details
11/13/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 5/30/2015 forward)

Earnings

Earnings History for Vascular Biogenics Ltd (NASDAQ:VBLT)
Earnings by Quarter for Vascular Biogenics Ltd (NASDAQ:VBLT)
Earnings History by Quarter for Vascular Biogenics Ltd (NASDAQ VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/20173/31/2017($0.17)($0.19)ViewN/AView Earnings Details
3/27/201712/31/2016($0.19)($0.18)ViewListenView Earnings Details
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics Ltd (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Vascular Biogenics Ltd (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics Ltd (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Vascular Biogenics Ltd (NASDAQ:VBLT)
Latest Headlines for Vascular Biogenics Ltd (NASDAQ:VBLT)
Source:
DateHeadline
seekingalpha.com logoVascular Biogenics: An Under-The-Radar Oncology Play Near $6 - Seeking Alpha
seekingalpha.com - May 26 at 8:19 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Releases Earnings Results
www.americanbankingnews.com - May 16 at 6:14 PM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 16 at 2:08 PM
finance.yahoo.com logoInvestor Network: Vascular Biogenics Ltd. to Host Earnings Call
finance.yahoo.com - May 15 at 8:37 AM
finance.yahoo.com logoVBL Therapeutics Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 8:37 AM
finance.yahoo.com logoVascular Biogenics reports 1Q loss
finance.yahoo.com - May 15 at 8:37 AM
finance.yahoo.com logoVBL Therapeutics to Report First Quarter 2017 Results on May 15
finance.yahoo.com - May 3 at 9:58 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 2 at 10:20 AM
americanbankingnews.com logo Brokerages Expect Vascular Biogenics Ltd (VBLT) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - May 1 at 11:00 AM
americanbankingnews.com logoVascular Biogenics (VBLT) Given Daily Coverage Optimism Rating of 0.04
www.americanbankingnews.com - April 30 at 9:04 AM
americanbankingnews.com logoVascular Biogenics (VBLT) Given Daily Media Impact Score of 0.31
www.americanbankingnews.com - April 27 at 12:02 PM
finance.yahoo.com logoVBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences
finance.yahoo.com - April 25 at 8:54 AM
americanbankingnews.com logoVascular Biogenics (VBLT) Given News Sentiment Rating of 0.15
www.americanbankingnews.com - April 24 at 12:37 PM
americanbankingnews.com logoVascular Biogenics (VBLT) Earns Daily Media Impact Rating of 0.15
www.americanbankingnews.com - April 21 at 9:35 PM
americanbankingnews.com logoVascular Biogenics (VBLT) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 1:20 PM
americanbankingnews.com logoVascular Biogenics (VBLT) Earning Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 15 at 8:09 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Short Interest Down 18.3% in March
www.americanbankingnews.com - April 11 at 9:55 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 7 at 10:25 PM
finance.yahoo.com logoVBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
finance.yahoo.com - April 7 at 1:18 PM
finance.yahoo.com logoVASCULAR BIOGENICS LTD. Financials
finance.yahoo.com - March 31 at 6:26 AM
seekingalpha.com logoVascular Biogenics' (VBLT) CEO, Dror Harats on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 29 at 10:50 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - March 28 at 11:50 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Announces Earnings Results
www.americanbankingnews.com - March 28 at 9:05 AM
finance.yahoo.com logoEdited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT
finance.yahoo.com - March 28 at 8:29 AM
finance.yahoo.com logoVBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference
finance.yahoo.com - March 28 at 8:29 AM
biz.yahoo.com logoQ4 2016 Vascular Biogenics Ltd Earnings Release - Before Market Open
us.rd.yahoo.com - March 27 at 8:25 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 27 at 8:25 AM
biz.yahoo.com logoVascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 27 at 8:25 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 25 at 7:29 AM
americanbankingnews.com logoVascular Biogenics Ltd (VBLT) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 24 at 10:13 PM
finance.yahoo.com logoVBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology
finance.yahoo.com - March 23 at 3:50 PM
finance.yahoo.com logoVBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 16 at 5:40 AM
finance.yahoo.com logoVBL Therapeutics to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 8:27 AM
finance.yahoo.com logoVBL Therapeutics to Report Full-Year 2016 Financial Results on March 27
finance.yahoo.com - March 3 at 5:11 AM
investopedia.com logoVBL's Thyroid Cancer Drug Clears Phase 2 (VBLT)
www.investopedia.com - February 22 at 10:46 AM
us.rd.yahoo.com logoVBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
us.rd.yahoo.com - February 22 at 10:46 AM
investopedia.com logoVBL Therapeutics Thyroid Cancer Drug Clears Phase 2
www.investopedia.com - February 22 at 10:46 AM
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $11 PT on Vascular Biogenics (VBLT); Phase 2a Thyroid Cancer Drug ... - StreetInsider.com
www.streetinsider.com - February 21 at 4:25 PM
finance.yahoo.com logoVBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 10:39 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
us.rd.yahoo.com - February 1 at 7:17 AM
finance.yahoo.com logoVBL Therapeutics Provides Year End 2016 Corporate Update
finance.yahoo.com - January 10 at 4:47 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
us.rd.yahoo.com - December 5 at 8:24 AM
us.rd.yahoo.com logo7:02 am Vascular Biogenics announces that the independent DSMC recommended that the Phase 3 GLOBE study investigating ofranergene obadenovec in recurrent glioblastoma study continue as planned
us.rd.yahoo.com - December 5 at 8:24 AM
streetinsider.com logoVBL Therapeutics (VBLT) Reports $20M at the Market Offering of Ordinary Shares
www.streetinsider.com - December 2 at 10:26 AM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data
www.streetinsider.com - November 29 at 4:01 PM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data
www.streetinsider.com - November 29 at 4:01 PM
nasdaq.com logoPre-Market Most Active for Nov 29, 2016 : MT, VALE, ASML, BAC, PBR, CHK, FCX, FOLD, NVLS, ARIA, AAPL, VBLT - Nasdaq
www.nasdaq.com - November 29 at 12:40 PM
finance.yahoo.com logoVBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer
finance.yahoo.com - November 29 at 12:40 PM
finance.yahoo.com logo7:02 am VBL Therapeutics announces top-line results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer
finance.yahoo.com - November 29 at 12:40 PM
finance.yahoo.com logoVBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
finance.yahoo.com - November 23 at 11:36 AM

Social

Chart

Vascular Biogenics Ltd (VBLT) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by MarketBeat.com Staff